Stockreport

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

argenx SE - American Depositary Shares  (ARGX) 
PDF          RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker m [Read more]